Enzyme replacement therapy: lessons learned and emerging questions

Bibliography

• Vanier MT. Lysosomal diseases: biochemical pathways and investigations. Handb Clin Neurol 2013;113:1695-9
   PubMedGoogle Scholar
• de Duve C. The lysosome turns fifty. Nat Cell Biol 2005;7(9):847-9
   PubMed Web of Science ®Google Scholar
• Braulke T, Bonifacino JS. Sorting of lysosomal proteins. Biochim Biophys Acta 2009;1793(4):605-14
   PubMed Web of Science ®Google Scholar
• Kornfeld S, Mellman I. The biogenesis of lysosomes. Annu Rev Cell Biol 1989;5:483-525
   PubMedGoogle Scholar
• Ghosh P, Dahms NM, Kornfeld S. Mannose 6-phosphate receptors: new twists in the tale. Nat Rev Mol Cell Biol 2003;4(3):202-12
   PubMed Web of Science ®Google Scholar
• Coutinho MF, Prata MJ, Alves S. A shortcut to the lysosome: the mannose-6-phosphate-independent pathway. Mol Genet Metab 2012;107(3):257-66
   PubMedGoogle Scholar
• Gandhi NS, Mancera RL. The structure of glycosaminoglycans and their interactions with proteins. Chem Biol Drug Des 2008;72(6):455-82
   PubMed Web of Science ®Google Scholar
• Settembre C, Fraldi A, Rubinsztein DC, Ballabio A. Lysosomal storage diseases as disorders of autophagy. Autophagy 2008;4(1):113-14
   PubMed Web of Science ®Google Scholar
• Fratantoni JC, Hall CW, Neufeld EF. Hurler and Hunter syndromes: mutual correction of the defect in cultured fibroblasts. Science 1968;162(3853):570-2
   PubMed Web of Science ®Google Scholar
• Ferrro WG, Guttmacher AE. New therapeutic approaches to mendelian disorders. N Engl J Med 2010;363(9):852-63
   PubMedGoogle Scholar
• Brady RO, Tallman JF, Johnson WG, et al. Replacement therapy for inherited enzyme deficiency. Use of purified ceramidetrihexosidase in Fabry’s disease. N Engl J Med 1973;289(1):9-14
   PubMed Web of Science ®Google Scholar
• Hickman S, Neufeld EF. A hypothesis for I-cell disease: defective hydrolases that do not enter lysosomes. Biochem Biophys Res Commun 1972;49(4):992-9
   PubMedGoogle Scholar
• Kornfeld S. Trafficking of lysosomal enzymes in normal and disease states. J Clin Invest 1986;77(1):1-6
   PubMedGoogle Scholar
• Valayannopoulos V. Enzyme replacement therapy and substrate reduction therapy in lysosomal storage disorders with neurological expression. Handb Clin Neurol 2013;113:1851-7
   PubMedGoogle Scholar
• Barton NW, Brady RO, Dambrosia JM, et al. Replacement therapy for inherited enzyme deficiency – macrophage-targeted glucocerebrosidase for Gaucher’s disease. N Engl J Med 1991;324(21):1464-70
   PubMed Web of Science ®Google Scholar
• Burrow TA, Hopkin RJ, Leslie ND, et al. Enzyme reconstitution/replacement therapy for lysosomal storage diseases. Curr Opin Pediatr 2007;19(6):628-35
   PubMed Web of Science ®Google Scholar
• Hille-Rehfeld A. Mannose 6-phosphate receptors in sorting and transport of lysosomal enzymes. Biochim Biophys Acta 1995;1241(2):177-94
   PubMedGoogle Scholar
• Kornfeld S. Lysosomal enzyme targeting. Biochem Soc Trans 1990;18(3):367-74
   PubMedGoogle Scholar
• Deegan PB, Cox TM. Imiglucerase in the treatment of Gaucher disease: a history and perspective. Drug Des Devel Ther 2012;6:81-106
   PubMed Web of Science ®Google Scholar
• Grabowski GA, Barton NW, Pastores G, et al. Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann Intern Med 1995;122(1):33-9
   PubMed Web of Science ®Google Scholar
• Martins AM, Valadares ER, Porta G, et al. Recommendations on diagnosis, treatment, and monitoring for Gaucher disease. J Pediatr 2009;155(4 Suppl):S10-18
   PubMed Web of Science ®Google Scholar
• Charrow J, Dulisse B, Grabowski GA, Weinreb NJ. The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease. Clin Genet 2007;71(3):205-11
   PubMed Web of Science ®Google Scholar
• Wenstrup RJ, Kacena KA, Kaplan P, et al. Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease. J Bone Miner Res 2007;22(1):119-26
   PubMed Web of Science ®Google Scholar
• Doneda D, Lopes AL, Teixeira BC, et al. Ghrelin, leptin and adiponectin levels in Gaucher disease type I patients on enzyme replacement therapy. Clin Nutr 2014. [Epub ahead of print]
   PubMedGoogle Scholar
• Langeveld M, de Fost M, Aerts JM, et al. Overweight, insulin resistance and type II diabetes in type I Gaucher disease patients in relation to enzyme replacement therapy. Blood Cells Mol Dis 2008;40(3):428-32
   PubMedGoogle Scholar
• Vellodi A, Tylki-Szymanska A, Davies EH, et al. Management of neuronopathic Gaucher disease: revised recommendations. J Inherit Metab Dis 2009;32(5):660-4
   PubMed Web of Science ®Google Scholar
• Rombach SM, Smid BE, Linthorst GE, et al. Natural course of Fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta-analysis: effectiveness of ERT in different disease stages. J Inherit Metab Dis 2014;37(3):341-52
   PubMed Web of Science ®Google Scholar
• Rombach SM, Smid BE, Bouwman MG, et al. Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain. Orphanet J Rare Dis 2013;8:47
   PubMed Web of Science ®Google Scholar
• Nicolino M, Byrne B, Wraith JE, et al. Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease. Genet Med 2009;11(3):210-19
   PubMed Web of Science ®Google Scholar
• Kishnani PS, Corzo D, Leslie ND, et al. Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease. Pediatr Res 2009;66(3):329-35
   PubMed Web of Science ®Google Scholar
• Kishnani PS, Corzo D, Nicolino M, et al. Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology 2007;68(2):99-109
   PubMed Web of Science ®Google Scholar
• Prater SN, Banugaria SG, DeArmey SM, et al. The emerging phenotype of long-term survivors with infantile Pompe disease. Genet Med 2012;14(9):800-10
   PubMed Web of Science ®Google Scholar
• van Gelder CM, van Capelle CI, Ebbink BJ, et al. Facial-muscle weakness, speech disorders and dysphagia are common in patients with classic infantile Pompe disease treated with enzyme therapy. J Inherit Metab Dis 2012;35(3):505-11
   PubMed Web of Science ®Google Scholar
• Prater SN, Patel TT, Buckley AF, et al. Skeletal muscle pathology of infantile Pompe disease during long-term enzyme replacement therapy. Orphanet J Rare Dis 2013;8(1):90
   PubMedGoogle Scholar
• Kishnani PS, Nicolino M, Voit T, et al. Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease. J Pediatr 2006;149(1):89-97
   PubMed Web of Science ®Google Scholar
• Hawes ML, Kennedy W, O’Callaghan MW, Thurberg BL. Differential muscular glycogen clearance after enzyme replacement therapy in a mouse model of Pompe disease. Mol Genet Metab 2007;91(4):343-51
   PubMedGoogle Scholar
• Raben N, Takikita S, Pittis MG, et al. Deconstructing Pompe disease by analyzing single muscle fibers: to see a world in a grain of sand. Autophagy 2007;3(6):546-52
   PubMed Web of Science ®Google Scholar
• de Vries JM, van der Beek NA, Kroos MA, et al. High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa. Mol Genet Metab 2010;101(4):338-45
   PubMed Web of Science ®Google Scholar
• Lachmann R, Schoser B. The clinical relevance of outcomes used in late-onset Pompe disease: can we do better? Orphanet J Rare Dis 2013;8(1):160
   PubMedGoogle Scholar
• Beck M. Alglucosidase alfa: long term use in the treatment of patients with Pompe disease. Ther Clin Risk Manag 2009;5:767-72
   PubMedGoogle Scholar
• Angelini C. State of the art in muscle glycogenoses. Acta Myol 2010;29(2):339-42
   PubMedGoogle Scholar
• Filosto M, Todeschini A, Cotelli MS, et al. Non-muscle involvement in late-onset glycogenosis II. Acta Myol 2013;32(2):91-4
   PubMedGoogle Scholar
• Clarke LA, Wraith JE, Beck M, et al. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics 2009;123(1):229-40
   PubMed Web of Science ®Google Scholar
• Kakkis ED, Muenzer J, Tiller GE, et al. Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med 2001;344(3):182-8
   PubMed Web of Science ®Google Scholar
• Wraith JE, Clarke LA, Beck M, et al. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). J Pediatr 2004;144(5):581-8
   PubMed Web of Science ®Google Scholar
• Muenzer J, Gucsavas-Calikoglu M, McCandless SE, et al. A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome). Mol Genet Metab 2007;90(3):329-37
   PubMed Web of Science ®Google Scholar
• Muenzer J, Wraith JE, Beck M, et al. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med 2006;8(8):465-73
   PubMed Web of Science ®Google Scholar
• Wraith JE, Scarpa M, Beck M, et al. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr 2008;167(3):267-77
   PubMed Web of Science ®Google Scholar
• Harmatz P, Giugliani R, Schwartz I, et al. Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. J Pediatr 2006;148(4):533-9
   PubMed Web of Science ®Google Scholar
• Horovitz DD, Magalhaes TS, Acosta A, et al. Enzyme replacement therapy with galsulfase in 34 children younger than five years of age with MPS VI. Mol Genet Metab 2013;109(1):62-9
   PubMed Web of Science ®Google Scholar
• Harmatz PR, Garcia P, Guffon N, et al. Galsulfase (Naglazyme(R)) therapy in infants with mucopolysaccharidosis VI. J Inherit Metab Dis 2014;37(2):277-87
   PubMedGoogle Scholar
• Giugliani R, Lampe C, Guffon N, et al. Natural history and galsulfase treatment in mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome)-10-year follow-up of patients who previously participated in an MPS VI survey study. Am J Med Genet A 2014;164A(8):1953-64
   PubMedGoogle Scholar
• Schweighardt B, Tompkins T, Lau K, et al. Immunogenicity of elosulfase alfa, an enzyme replacement therapy in patients with morquio a syndrome: results from MOR-004, a phase III trial. Clin Ther 2014. [ Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Grubb JH, Vogler C, Sly WS. New strategies for enzyme replacement therapy for lysosomal storage diseases. Rejuvenation Res 2010;13(2-3):229-36
   PubMed Web of Science ®Google Scholar
• Sly WS, Vogler C. The final frontier – crossing the blood-brain barrier. EMBO Mol Med 2013;5(5):655-7
   PubMedGoogle Scholar
• Roney C, Kulkarni P, Arora V, et al. Targeted nanoparticles for drug delivery through the blood-brain barrier for Alzheimer’s disease. J Control Release 2005;108(2-3):193-214
   PubMedGoogle Scholar
• Kanwar JR, Sriramoju B, Kanwar RK. Neurological disorders and therapeutics targeted to surmount the blood-brain barrier. Int J Nanomedicine 2012;7:3259-78
   PubMed Web of Science ®Google Scholar
• Abbott NJ, Patabendige AA, Dolman DE, et al. Structure and function of the blood-brain barrier. Neurobiol Dis 2010;37(1):13-25
   PubMed Web of Science ®Google Scholar
• Urayama A, Grubb JH, Sly WS, Banks WA. Developmentally regulated mannose 6-phosphate receptor-mediated transport of a lysosomal enzyme across the blood-brain barrier. Proc Natl Acad Sci USA 2004;101(34):12658-63
   PubMedGoogle Scholar
• Anson DS, McIntyre C, Byers S. Therapies for neurological disease in the mucopolysaccharidoses. Curr Gene Ther 2011;11(2):132-43
   PubMedGoogle Scholar
• Munoz-Rojas MV, Horovitz DD, Jardim LB, et al. Intrathecal administration of recombinant human N-acetylgalactosamine 4-sulfatase to a MPS VI patient with pachymeningitis cervicalis. Mol Genet Metab 2010;99(4):346-50
   PubMed Web of Science ®Google Scholar
• Modi M, Singla V, Khandelwal N, et al. Maroteaux–lamy syndrome (mucopolysaccharidosis VI) presenting as familial myelopathy. Int J Neurosci 2011;121(6):337-40
   PubMed Web of Science ®Google Scholar
• Horovitz DD, Magalhaes TD, AP EC, et al. Spinal cord compression in young children with type VI mucopolysaccharidosis. Mol Genet Metab 2011;104(3):295-300
   PubMedGoogle Scholar
• Jurecka A, Opoka-Winiarska V, Jurkiewicz E, et al. Spinal cord compression in Maroteaux-Lamy syndrome: case report and review of the literature with effects of enzyme replacement therapy. Pediatr Neurosurg 2012;48(3):191-8
   PubMedGoogle Scholar
• Tomatsu S, Almeciga-Diaz CJ, Barbosa H, et al. Therapies of mucopolysaccharidosis IVA (Morquio A syndrome). Expert Opin Orphan Drugs 2013;1(10):805-18
   PubMed Web of Science ®Google Scholar
• Giugliani R, Federhen A, Rojas MV, et al. Mucopolysaccharidosis I, II, and VI: brief review and guidelines for treatment. Genet Mol Biol 2010;33(4):589-604
   PubMed Web of Science ®Google Scholar
• Harmatz P. Enzyme replacement therapy with galsulfase for mucopolysaccharidosis VI: clinical facts and figures. Turk J Pediatr 2010;52(5):443-9
   PubMedGoogle Scholar
• Tylki-Szymanska A, Marucha J, Jurecka A, et al. Efficacy of recombinant human alpha-L-iduronidase (laronidase) on restricted range of motion of upper extremities in mucopolysaccharidosis type I patients. J Inherit Metab Dis 2010;33(2):151-7
   PubMedGoogle Scholar
• Zuber Z, Rozdzynska-Swiatkowska A, Jurecka A, Tylki-Szymanska A. The effect of recombinant human iduronate-2-sulfatase (idursulfase) on growth in young patients with mucopolysaccharidosis type II. PLoS One 2014;9(1):e85074
   Web of Science ®Google Scholar
• Muenzer J. Early initiation of enzyme replacement therapy for the mucopolysaccharidoses. Mol Genet Metab 2014;111(2):63-72
   PubMed Web of Science ®Google Scholar
• Braunlin E, Rosenfeld H, Kampmann C, et al. Enzyme replacement therapy for mucopolysaccharidosis VI: long-term cardiac effects of galsulfase (Naglazyme®) therapy. J Inherit Metab Dis 2013;36(2):385-94
   PubMed Web of Science ®Google Scholar
• Braunlin E, Berry J, Whitley C. Cardiac findings after enzyme replacement therapy for mucopolysaccharidosis type I. Am J Cardiol 2006;98(3):416-18
   PubMedGoogle Scholar
• Braunlin E, Mackey-Bojack S, Panoskaltsis-Mortari A, et al. Cardiac functional and histopathologic findings in humans and mice with mucopolysaccharidosis type I: implications for assessment of therapeutic interventions in hurler syndrome. Pediatr Res 2006;59(1):27-32
   PubMedGoogle Scholar
• McGill JJ, Inwood AC, Coman DJ, et al. Enzyme replacement therapy for mucopolysaccharidosis VI from 8 weeks of age – a sibling control study. Clin Genet 2010;77(5):492-8
   PubMed Web of Science ®Google Scholar
• Tylki-Szymanska A, Jurecka A, Zuber Z, et al. Enzyme replacement therapy for mucopolysaccharidosis II from 3 months of age: 3-year follow-up. Acta Paediatr 2012;101(1):e42-7
   PubMed Web of Science ®Google Scholar
• Gabrielli O, Clarke LA, Bruni S, Coppa GV. Enzyme-replacement therapy in a 5-month-old boy with attenuated presymptomatic MPS I: 5-year follow-up. Pediatrics 2010;125(1):e183-7
   PubMed Web of Science ®Google Scholar
• Baldo G, Mayer FQ, Martinelli BZ, et al. Enzyme replacement therapy started at birth improves outcome in difficult-to-treat organs in mucopolysaccharidosis I mice. Mol Genet Metab 2013;109(1):33-40
   PubMed Web of Science ®Google Scholar
• Hinek A, Wilson SE. Impaired elastogenesis in Hurler disease: dermatan sulfate accumulation linked to deficiency in elastin-binding protein and elastic fiber assembly. Am J Pathol 2000;156(3):925-38
   PubMedGoogle Scholar
• Jurecka A, Marucha J, Jurkiewicz E, et al. Enzyme replacement therapy in an attenuated case of mucopolysaccharidosis type I (Scheie syndrome): a 6.5-year detailed follow-up. Pediatr Neurol 2012;47(6):461-5
   PubMedGoogle Scholar
• Tomanin R, Zanetti A, Avanzo F, et al. Clinical efficacy of enzyme replacement therapy in paediatric hunter patients, an independent study of 3.5 years. Orphanet J Rare Dis 2014;9(1):129
   PubMed Web of Science ®Google Scholar
• Sifuentes M, Doroshow R, Hoft R, et al. A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years. Mol Genet Metab 2007;90(2):171-80
   PubMedGoogle Scholar
• Brooks DA, Kakavanos R, Hopwood JJ. Significance of immune response to enzyme-replacement therapy for patients with a lysosomal storage disorder. Trends Mol Med 2003;9(10):450-3
   PubMedGoogle Scholar
• Hunt SV. Perspectives from B cell immunology: fact and fancy. Int J Clin Pharmacol Ther 2009;47(Suppl 1):S86-99
   PubMedGoogle Scholar
• Porter S. Human immune response to recombinant human proteins. J Pharm Sci 2001;90(1):1-11
   PubMed Web of Science ®Google Scholar
• Vedder AC, Breunig F, Donker-Koopman WE, et al. Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3. Mol Genet Metab 2008;94(3):319-25
   PubMedGoogle Scholar
• Hollak CE, Linthorst GE. Immune response to enzyme replacement therapy in Fabry disease: impact on clinical outcome? Mol Genet Metab 2009;96(1):1-3
   PubMedGoogle Scholar
• Richards SM, Olson TA, McPherson JM. Antibody response in patients with Gaucher disease after repeated infusion with macrophage-targeted glucocerebrosidase. Blood 1993;82(5):1402-9
   PubMedGoogle Scholar
• van der Ploeg AT, Clemens PR, Corzo D, et al. A randomized study of alglucosidase alfa in late-onset Pompe’s disease. N Engl J Med 2010;362(15):1396-406
   PubMed Web of Science ®Google Scholar
• Kishnani PS, Goldenberg PC, DeArmey SL, et al. Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. Mol Genet Metab 2010;99(1):26-33
   PubMed Web of Science ®Google Scholar
• Amalfitano A, Bengur AR, Morse RP, et al. Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. Genet Med 2001;3(2):132-8
   PubMed Web of Science ®Google Scholar
• Neufeld EF, Muenzer J. The mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS, editors. The metabolic and molecular basis of inherited disease. McGraw-Hill; New York: 2001. p. 3421-52
   Google Scholar
• Brands MM, Hoogeveen-Westerveld M, Kroos MA, et al. Mucopolysaccharidosis type VI phenotypes-genotypes and antibody response to galsulfase. Orphanet J Rare Dis 2013;8(1):51
   PubMedGoogle Scholar
• Banugaria SG, Prater SN, Ng YK, et al. The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease. Genet Med 2011;13(8):729-36
   PubMed Web of Science ®Google Scholar
• Settembre C, Ballabio A. Cell metabolism: autophagy transcribed. Nature 2014;516(7529):40-1
   PubMed Web of Science ®Google Scholar
• Settembre C, Di Malta C, Polito VA, et al. TFEB links autophagy to lysosomal biogenesis. Science 2011;332(6036):1429-33
   PubMed Web of Science ®Google Scholar
• Shea L, Raben N. Autophagy in skeletal muscle: implications for Pompe disease. Int J Clin Pharmacol Ther 2009;47(Suppl 1):S42-7
   PubMedGoogle Scholar
• Coppa GV, Buzzega D, Zampini L, et al. Effect of 6 years of enzyme replacement therapy on plasma and urine glycosaminoglycans in attenuated MPS I patients. Glycobiology 2010;20(10):1259-73
   PubMedGoogle Scholar
• Kakkis ED. Enzyme replacement therapy for the mucopolysaccharide storage disorders. Expert Opin Investig Drugs 2002;11(5):675-85
   PubMed Web of Science ®Google Scholar
• Connock M, Juarez-Garcia A, Frew E, et al. A systematic review of the clinical effectiveness and cost-effectiveness of enzyme replacement therapies for Fabry’s disease and mucopolysaccharidosis type 1. Health Technol Assess 2006;10(20):iii-v; ix-113
   Google Scholar
• van der Meijden JC, Gungor D, Kruijshaar ME, et al. Ten years of the international Pompe survey: patient reported outcomes as a reliable tool for studying treated and untreated children and adults with non-classic Pompe disease. J Inherit Metab Dis 2014. [ Epub ahead of print]
   PubMedGoogle Scholar
• Hollak CE, Aerts JM, Ayme S, Manuel J. Limitations of drug registries to evaluate orphan medicinal products for the treatment of lysosomal storage disorders. Orphanet J Rare Dis 2011;6:16
   PubMed Web of Science ®Google Scholar
• Wraith JE. Enzyme replacement therapy in mucopolysaccharidosis type I: progress and emerging difficulties. J Inherit Metab Dis 2001;24(2):245-50
   PubMedGoogle Scholar
• Elstein D, Abrahamov A, Hadas-Halpern I, Zimran A. Withdrawal of enzyme replacement therapy in Gaucher’s disease. Br J Haematol 2000;110(2):488-92
   PubMedGoogle Scholar
• Czartoryska B, Tylki-Szymanska A, Lugowska A. Changes in serum chitotriosidase activity with cessation of replacement enzyme (cerebrosidase) administration in Gaucher disease. Clin Biochem 2000;33(2):147-9
   PubMedGoogle Scholar
• vom Dahl S, Poll LW, Haussinger D. Clinical monitoring after cessation of enzyme replacement therapy in M. Gaucher. Br J Haematol 2001;113(4):1084-7
   PubMed Web of Science ®Google Scholar
• Grinzaid KA, Geller E, Hanna SL, Elsas LJII. Cessation of enzyme replacement therapy in Gaucher disease. Genet Med 2002;4(6):427-33
   PubMed Web of Science ®Google Scholar
• Barton NW, Furbish FS, Murray GJ, et al. Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease. Proc Natl Acad Sci USA 1990;87(5):1913-16
   PubMed Web of Science ®Google Scholar
• Linthorst GE, Germain DP, Hollak CE, et al. Expert opinion on temporary treatment recommendations for Fabry disease during the shortage of enzyme replacement therapy (ERT). Mol Genet Metab 2011;102(1):99-102
   PubMed Web of Science ®Google Scholar
• Schwartz IV, Karam S, Ashton-Prolla P, et al. Effects of imilglucerase withdrawal on an adult with Gaucher disease. Br J Haematol 2001;113(4):1089
   PubMedGoogle Scholar
• Toth J, Erdos M, Marodi L. Rebound hepatosplenomegaly in type 1 Gaucher disease. Eur J Haematol 2003;70(2):125-8
   PubMedGoogle Scholar
• Drelichman G, Ponce E, Basack N, et al. Clinical consequences of interrupting enzyme replacement therapy in children with type 1 Gaucher disease. J Pediatr 2007;151(2):197-201
   PubMedGoogle Scholar
• Hollak CE, vom Dahl S, Aerts JM, et al. Force majeure: therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease. Blood Cells Mol Dis 2010;44(1):41-7
   PubMed Web of Science ®Google Scholar
• Barrot-Cortes E, Barrera-Chacon JM. Clinical consequences of reduced dosing schedule during treatment of a patient with pompe’s disease. Biol Ther 2011;12:1
   Google Scholar
• Anbu AT, Mercer J, Wraith JE. Effect of discontinuing of laronidase in a patient with mucopolysaccharidosis type I. J Inherit Metab Dis 2006;29(1):230-1
   PubMedGoogle Scholar
• Węgrzyn G, Tylki-Szymańska A, Liberek A, et al. Rapid deterioration of a patient with mucopolysaccharidosis type I during interruption of enzyme replacement therapy. Am J Med Genet A 2007;143A(16):1925-7
   PubMedGoogle Scholar
• Jurecka A, Zuber Z, Opoka-Winiarska V, et al. Effect of rapid cessation of enzyme replacement therapy: a report of 5 cases and a review of the literature. Mol Genet Metab 2012;107(3):508-12
   PubMedGoogle Scholar
• Jurecka A, Malinova V, Tylki-Szymanska A. Effect of rapid cessation of enzyme replacement therapy: a report of 5 more cases. Mol Genet Metab 2014;111(2):212-13
   PubMedGoogle Scholar
• van Dussen L, Biegstraaten M, Hollak CE, Dijkgraaf MG. Cost-effectiveness of enzyme replacement therapy for type 1 Gaucher disease. Orphanet J Rare Dis 2014;9(1):51
   PubMedGoogle Scholar
• Connock M, Burls A, Frew E, et al. The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher’s disease: a systematic review. Health Technol Assess 2006;10(24):iii-v; ix-136
   Web of Science ®Google Scholar
• Reuser AJ, Verheijen FW, Bali D, et al. The use of dried blood spot samples in the diagnosis of lysosomal storage disorders - Current status and perspectives. Mol Genet Metab 2011;104(1-2):144-8
   PubMed Web of Science ®Google Scholar
• Matern D, Oglesbee D, Tortorelli S. Newborn screening for lysosomal storage disorders and other neuronopathic conditions. Dev Disabil Res Rev 2013;17(3):247-53
   PubMedGoogle Scholar
• Spada M, Pagliardini S, Yasuda M, et al. High incidence of later-onset fabry disease revealed by newborn screening. Am J Hum Genet 2006;79(1):31-40
   PubMed Web of Science ®Google Scholar
• Parenti G, Moracci M, Fecarotta S, Andria G. Pharmacological chaperone therapy for lysosomal storage diseases. Future Med Chem 2014;6(9):1031-45
   PubMedGoogle Scholar